A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus

A Randomized, Single-Blind, Dose-Rising, Placebo-Controlled, Crossover Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus

This study will be the first evaluation of exenatide in adolescent subjects with type 2 diabetes mellitus and is designed to evaluate the blood levels of the drug (pharmacokinetics), the drug's biochemical and physiological effects (pharmacodynamics), and tolerability of exenatide in these subjects.

Inclusion Criteria:

• Treatment with diet and exercise alone or a stable dose of metformin, or sulfonylurea, or metformin plus a sulfonylurea for at least 3 months.
• Has HbA1c 6.0% to 11.0%, inclusive, at screening.
• Has a body weight of >= 50 kg at screening.

Exclusion Criteria:

• Received any investigational drug or has participated in any type of clinical trial within 3 months prior to screening.

• Currently participates in any other interventional study.

• Is currently treated with any of the following excluded medications:

  • Sulfonylurea chlorpropamide
  • Thiazolidinedione within 3 months of screening.
  • Αlpha glucosidase inhibitor within 3 months of screening.
  • Meglitinide within 3 months of screening.
  • Insulin within 3 months of screening.
  • Pramlintide within 3 months of screening.